14223-52-0

Upstream product

• 14223-45-1 p-tolyl isoselenocyanate 
• 3085-54-9 N-(4-methylphenyl)formamide 
• 106-49-0 p-toluidine 

Downstream Products

• 73937-33-4 4-nitro-benzaldehyde (4-phenyl-3-p-tolyl-3H-selenazol-2-ylidene)-hydrazone 
• 1401253-06-2 5-(4-methylphenylamino)-1,3,4-selenadiazol-2(3H)-one 
• 14223-62-2 Benzaldehyd-(4-p-tolyl-selenosemicarbazon) 
• 63528-62-1 5-(4-methyl-anilino)-3H-[1,3,4]selenadiazole-2-selone 
• 63528-61-0 5-(4-methyl-anilino)-3H-[1,3,4]selenadiazole-2-thione 

Relevant academic research and scientific papers

Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity

Kidney-type glutaminase [KGA/isoenzyme glutaminase C (GAC)] is becoming an important tumor metabolism target in cancer chemotherapy. Its allosteric inhibitor, CB839, showed early promise in cancer therapeutics but limited efficacy in in vivo cancer models. To improve the in vivo activity, we explored a bioisostere replacement of the sulfur atom in bis-2-(5-phenylacetamido-1,2,4-thiadiazol)ethyl sulfide and CB839 analogues with selenium using a novel synthesis of the selenadiazole moiety from carboxylic acids or nitriles. The resulting selenadiazole compounds showed enhanced KGA inhibition, more potent induction of reactive oxygen species, improved inhibition of cancer cells, and higher cellular and tumor accumulation than the corresponding sulfur-containing molecules. However, both CB839 and its selenium analogues show incomplete inhibition of the tested cancer cells, and a partial reduction in tumor size was observed in both the glutamine-dependent HCT116 and aggressive H22 liver cancer xenograft models. Despite this, tumor tissue damage and prolonged survival were observed in animals treated with the selenium analogue of CB839.

New selenosteroids as antiproliferative agents

Starting from natural steroids (diosgenin, hecogenin, smilagenin, estrone), we have prepared a wide panel of selenoderivatives, including benzoselenazolones, selenosemicarbazones, isoselenocyanates, selenoureas, selenocyanates and diselenides, with the aim of developing new families of potential chemotherapeutic agents. The modification of the organoselenium moieties, and their position on the steroid provided valuable information concerning the antiproliferative activities. Among all the families accessed herein, the best profile was achieved for selenoureas on the A ring of estrone, which exhibited GI50 values in the range 2.0-4.1 μM for all the tested tumor cell lines, with increased potency compared with commonly used chemotherapeutic agents, like 5-fluorouracil and cisplatin. Cell cycle analysis revealed that selenoureas induced accumulation of cells in the G1 phase of the cell cycle in the breast cancer cell lines HBL-100 and T-47D; therefore, a different mechanism than cisplatin, that induces cell cycle accumulation in the S phase as a result of DNA damage, must be involved. In the rest of the tumor cells, a slight increase of the S compartment was observed. Moreover, selenosteoids turned out to be excellent glutathione peroxidase (GPx) mimics for the catalytic removal of deleterious H2O2 (t1/2 8.0-22.5 min) and alkyl peroxides (t1/2 23.0-38.9 min) when used in substoichiometric amounts (1% molar ratio), thus providing a valuable tool for reducing the intrinsic oxidative stress in tumor progression.

An efficient one-pot synthesis of 2-amino-1,3,4-selenadiazoles

An efficient one-pot synthesis of 2-amino-1,3,4-selenadiazoles from isoselenocyanates, hydrazine hydrate and aromatic aldehydes has been developed. This approach provides a simple, mild and facile way to construct various derivatives in moderate to good y

One-pot synthesis of 5-arylamino-1,3,4-selenadiazol-2(3H)-ones from arylisoselenocyanates

A one-pot reaction of arylisoselenocyanates, hydrazine and bis(trichloromethyl) carbonate, in the presence of a base provides an efficient route for the synthesis of 5-arylamino-1,3,4-selenadiazol-2(3H)-ones in good to excellent yields. A plausible mechan